Trial to Assess the Safety and Tolerability of the Liquid Formulation of CAIV-T in Healthy Children.

NCT00192400 ↗

Phase 3 Completed 2160 enrolled MedImmune LLC Wyeth is now a wholly owned subsidiary of Pfizer · collab

RandomizedSingle-groupDouble-blindEct

Summary

The purpose of this study is to determine the efficacy of the liquid formulation of CAIV-T against culture confirmed influenza illness in healthy children aged at least 6 months and less than 36 months.

Timeline

Start: 2002-03
Primary completion: —
Completion: 2002-11

Publications

Bracco Neto H, Farhat CK, Tregnaghi MW, Madhi SA, Razmpour A, Palladino G, Small MG, Gruber WC, Forrest BD; D153-P504 LAIV Study Group. Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive children. Pediatr Infect Dis J. 2009 May;28(5):365-71. doi: 10.1097/INF.0b013e31819219b8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	FluMist	Vaccine	—	—

Indications

No indication recorded.